Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Increasing Healthcare Access Bolsters Sector
11 janv. 2023 04h48 HE
|
Research and Markets
Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ...
China Infliximab Market Investigation Report 2022: Sales 2017-2021, Major Manufacturers 2017-2021, Prices for Different Manufacturers 2021-2022 and Prospects 2022-2031
10 août 2022 05h28 HE
|
Research and Markets
Dublin, Aug. 10, 2022 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Infliximab Market 2022-2031" report has been added to ResearchAndMarkets.com's offering. According to this market...
Global TNF Alpha Inhibitors Market Report 2022-2026 & 2031 Featuring Major Players - AbbVie, Amgen, J&J, UCB, Novartis, Pfizer, Merck & Co, Janssen Biotech, Ablynx, and Momenta Pharmaceuticals
04 août 2022 07h04 HE
|
Research and Markets
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering. The global...
China's Infliximab Markets, 2016-2020 & 2021-2025 - Relevant Concepts, Sales, Major Manufacturers, Prices, Prospects
29 juil. 2021 08h33 HE
|
Research and Markets
Dublin, July 29, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Infliximab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Infliximab is a human-mouse...
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
20 juil. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
Global TNF Alpha Inhibitors Market Report 2020: Market is Expected to Recover and Reach $42.86 Billion in 2023 - Long-term Forecast to 2025 & 2030
29 mars 2021 04h53 HE
|
Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global...
Global $2.27 Billion Adalimumab, Infliximab and Etanercept Biosimilars Market to 2030
03 févr. 2021 04h43 HE
|
Research and Markets
Dublin, Feb. 03, 2021 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to...
Global Gastrointestinal Drugs Markets, 2019-2020 & 2027: Acid Neutralizers, Antidiarrheal and Laxatives, Anti-inflammatory Drugs, Antiemetic and Antinauseants, Biologics
24 nov. 2020 02h38 HE
|
Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Application; Distribution...
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
06 janv. 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab...
American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade)
10 févr. 2016 14h43 HE
|
American College of Rheumatology
ATLANTA, Feb. 10, 2016 (GLOBE NEWSWIRE) -- During a public meeting held Tuesday by the Food and Drug Administration (FDA)'s Arthritis Advisory Committee to review the license application of CT-P13,...